ABSTRACT
INTRODUCTION
Treatments for mental health disorders and smoking-related diseases account for substantial expenditure in all health care systems. At any time in the UK about one in six adults has a mental health disorder, typically anxiety, depression or schizophrenia, whilst the prevalence of smoking in this group, at 33% in 2007, is around 50% higher than in the general population [1] . Since people with mental health disorders are also more likely to smoke heavily, [2] this group accounts for as much as 42% of total national tobacco consumption. [1] In 2009/10 the economic cost to society of mental health disorders in the UK was approximately £105 billion. [3] Mental health services account for about 14% of the total annual National Health Service (NHS) budget and is the largest single category of NHS expenditure. Smoking is the leading avoidable cause of ill-health and premature mortality in the UK, and the cost of smoking-related ill-health to the NHS is approximately £5.17 billion, or 5.5% of the total NHS budget. [4] The high prevalence of smoking among people with mental health disorders makes the most common smoking-related illnesses, especially lung cancer, cardiovascular disease and chronic obstructive pulmonary disease (COPD), [5] particularly prevalent in this group, and these conditions account for much of the reduced life expectancy of people with mental health disorders. [6] This morbidity and mortality, and the economic costs that ensue, are entirely avoidable.
The high prevalence of smoking among people with mental health disorders, and the significant contribution that smoking makes to the increased morbidity and mortality 5 in this group, has been extensively documented and reflects the effects of an historical smoking culture within mental healthcare settings, smoking being used as a form of self-mediation by patients and control by staff, and a lack of awareness of smoking as an issue among professionals working with or caring for people with mental disorders. [6] The economic disadvantage experienced by many people with mental disorders as a result of unemployment and dependence on state benefits is also exacerbated by expenditure on smoking, which may further exacerbate ill-health.
Despite the significant health and financial impacts of smoking in this population there has been little research with regard to the economic burden. Improved understanding of the economic cost of smoking and its major determinants helps to inform policymakers and to motivate decisions to reduce the smoking rate and burden. The aim of this study is to estimate the economic costs of the health effects of cigarette smoking amongst people with mental disorders in the UK. This study was carried out as part of a wider assessment of the health effects of smoking among people with mental health disorders commissioned by the Royal College of Physicians. [6] 
METHOD
Based on the cost of illness approach, the avoidable economic burden of smoking in people with mental health disorders comprises three components: direct healthcare costs, indirect morbidity costs and indirect mortality costs due to smoking-related diseases. [7] The target population in this study focuses on UK adults aged 16 and over with any mental health diagnosis. Costs were assessed from the NHS and Personal
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Social Services (PSS) perspective. All costs were estimated in UK pounds (£) in the 2009/10 financial year. The Hospital and Community Health Services (HCHS) Pay and Prices Index was used to inflate cost estimates from other time periods. [8] Prevalence of mental disorders and smoking rates Mental health disorders are usually categorised into two groups. Neurotic disorders (common mental disorder/CMD) consist of mixed anxiety/depressive disorder, generalised anxiety disorder, depressive episodes, any phobia, obsessive compulsive disorder and panic disorder. Psychotic disorders (severe mental health disorders/SMD) include schizophrenia and affective psychosis, such as bi-polar disorder. Table 1 summarises the prevalence of mental disorders and the prevalence of current, ex-and never smoking among adults in the UK with these conditions. The prevalence of each mental health disorder was taken from the 2007 Adult Psychiatric Morbidity Survey (APMS), [1] and the prevalence of current smoking and ex-smoking for those with neurotic disorders from the study by Coulthard et al. [9] It is more difficult to obtain data for people with psychotic disorders in national surveys of the general population as many live in institutions or are homeless; however, a survey of residents in psychiatric institutions conducted by Meltzer and colleagues in 1996 reported that over 70% of residents were smokers and the highest smoking rates (78%) were found among males diagnosed with schizophrenia. [2] 
Smoking-attributable proportion
To estimate the ensuing economic costs for smoking related diseases we have used the attributable risk approach originally devised by Levin, [10] and widely used in estimation of smoking-attributable health outcomes in the literature. The smokingattributable proportion (SAP) of disease in current and former smokers compared to never-smokers can be estimated from the relative risks of disease and prevalence of exposure using the formula (I):
Where: SAP = smoking attributable proportion p cur = proportion who are current smokers r cur = relative risk for current compared with never smokers p ex = proportion who are ex-smokers r ex = relative risk for ex compared with never smokers SAP quantifies the fraction of total costs incurred as a consequence of smoking. The SAP is used to compute both direct medical costs and indirect productivity losses in the following sections.
Direct medical costs 9
Direct medical costs are defined as the monetary value of resources consumed as a result of treating smoking-related disease. In this study, direct healthcare costs included costs of hospital admissions, outpatient visits, general practitioner (GP) and practice nurse consultations and prescriptions related to smoking-related diseases among people with mental disorders. The costs of each healthcare service attributable to smoking were calculated using the following equation (II). Similarly, relative risks of outpatient and primary care utilisation by current smokers and ex-smokers compared to never smokers are listed in Table A3 (Appendix). The data were obtained from reports of health service use and the UK General Household
Survey in 2006.[14]
There were 926.7 million prescription items dispensed in 2010 and the average net ingredient cost (NIC) per prescription item was £9.53. [15] It is reported that 62% of consultations were conducted by GPs and 34% were undertaken by practice nurses The cost of outpatient and primary care utilisation for other UK jurisdictions were extrapolated from the estimates for England using 2010 population estimates where published data were not available [17, 18] .
Indirect morbidity costs
The indirect costs of smoking among people with mental disorders were estimated using the human capital approach [7] . Cigarette smokers are more likely to be absent from work due to various smoking-related diseases compared to never-smokers [19] .
In this study, the indirect morbidity costs of smoking were estimated as the economic 11 value of lost productivity from increased rates of absenteeism associated with smoking using equation (III).
Where SAI = smoking-attributable indirect morbidity costs from the productivity losses due to smokingrelated diseases SAP ikl = smoking attributable proportion of indirect morbidity costs for smoking-related disease j among people with mental disorder k by gender l TWLD jk = total yearly work-loss days due to disease j among population subgroup k by gender l
ERN = average national daily earnings
Smoking-attributable costs of work days lost were calculated by multiplying smokingattributable work days lost by average income. The Office for National Statistics report that the employment rate for people with a common mental disorder was 57%
in 2000, in which 40% are working full time and a further 17% working part time.
Among people with severe mental disorders, only 9% work full time and 19% work part time. [20] The mean number of days absent from work in the past year for people with common and severe mental disorders were reported as 19 days and 67 days respectively. [20] A recently-published systematic review reported that the relative risk of absence for current smokers versus never-smokers was 1.33 (95% CI: 1.25 -1.41) and the relative risk of absenteeism for ex-smokers versus never-smokers was 1.14 (95% CI: 1.08 -1.21) [21] . Average earnings in the UK were used to value productivity losses due to smoking-related diseases as reported in an annual survey of hours and earning by the Office for National Statistics [22]
Indirect mortality costs
A further aspect of the economic cost of smoking is the value of smoking-attributable lost productivity from premature death. In this study, years of potential life lost Indirect mortality costs were calculated to present the monetary value of lives lost due to smoking-attributable premature death among people with mental disorder. The indirect mortality cost was calculated by taking the net present value of future productivity (PVFP) using the following equation (IV) [7] .
Where SAM = smoking-attributable mortality cost SAP jkml = smoking attributable proportion of indirect morbidity costs for smoking-related disease j among people with mental disorder k, by different age-group m and gender l NDEATH jml = number of death from disease j for population subgroup, by different age-group m and gender l PVLE ml = total discounted present value of lifetime earnings for population subgroup, by different agegroup m and gender l
The number of deaths from smoking-attributable diseases was estimated for males and females separately using 10-year age groups. The number of deaths was then used to estimate residual years of working life by subtracting age at death from retirement age (65 years). The next step was to attach the average earnings to the remaining working years and adjust the income into present values, adopting a discount rate of 3.5% following National Institute for Health and Care Excellence (NICE)
guidelines.
[26]
RESULTS
An estimated 3 million adults aged 16 and over with mental disorders were smokers in the 2009/10 financial year in the UK. [6] The total smoking-attributable costs were estimated at £2.34 billion in 2009/10 in the UK (Table 2) . Costs are distributed approximately equally between the three cost components. Approximately £719 million (31%) was spent each year on treating diseases caused by smoking amongst people with mental health disorders. Productivity losses due to smoking-related diseases were estimated to be £823 million (35%) for work-related absenteeism and
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£797 million (34%) associated with premature mortality. GPs to treat smoking-related diseases among people with mental disorders and generated a cost of £179 million to the NHS. The estimated cost of outpatient attendances attributable to smoking was £71 million which accounted for 10% of all direct medical costs for people with mental health disorders.
Direct medical costs

Indirect morbidity costs
The annual productivity loss due to excess absenteeism associated with smoking attributable morbidity in the UK was estimated at approximately £823 million among people suffering from mental health disorders in 2009/10. Table 4 lists employment status and average weekly earnings for people with and without mental disorders. Table 6 also reports the economic cost of premature mortality caused by smokingrelated diseases. Deaths from smoking in people with mental disorders were estimated to result in the loss of around £797 million in the UK in 2009/10 and over half (52%)
Indirect mortality cost
of mortality costs were incurred by male smokers. Nearly 50% (£366 million) of indirect costs were associated with people who have mixed anxiety and depressive disorder, followed by smokers with generalised anxiety disorder (23%). Table 7 shows the number of premature deaths caused by smoking and the indirect mortality cost among people with mental health disorders by smoking-attributable disease type. In the UK a total of 23,945 deaths of adults with mental disorders were attributable to smoking in 2010, 12,389 for men and 11,556 for women. It is estimated that 39% (9,280) of all deaths due to respiratory diseases and 31% (7,425) of all cancer deaths were attributable to smoking among people with mental disorders. In addition, an estimated 28% (6,758) of deaths from cardiovascular diseases and 2%
(482) of deaths from diseases of the digestive system were attributable to smoking.
Smoking increases the excess risk of cardiovascular death and some types of cancer among people with mental disorders, and results in a future productivity loss of £493 million and £111 million, respectively. 
DISCUSSION
Smoking rates are substantially higher in disadvantaged groups, such as people with mental disorders, compared with the general population [2] resulting in a much greater incidence of smoking-related morbidity and mortality in these groups. Among people with mental health disorders, smoking has historically been widely considered to be a self-medication mechanism, which in part explains the sustained difficulties faced by medical services in preventing smoking in this group [6] . This paper is to our knowledge the first attempt to estimate the overall economic burden due to smoking and smoking-related diseases among people with mental health disorders in the UK.
We estimate that there are about three million people with mental disorders in the UK who also smoke and are hence susceptible to smoking related-disease. We estimate that the direct medical cost to the NHS in 2010 of treating these smokers for diseases caused by smoking was £719 million, and that smoking in this group also accounts for around 35% of work-related absenteeism due to smoking, costing £823 million in lost productivity, and about 34% of premature mortality, costing £797 million.
Since there is little research examining the economic burden of smoking among 20 people with mental illnesses, comparisons with other studies are largely limited to those involving the general population. A recent study by Callum and colleagues employed a similar method to estimate the direct medical cost to the NHS in the general population [14] , and using the 1996 smoking prevalence of 28.5% estimated the direct cost of treating smoking-related diseases to the NHS at £2.7 billion in
England. This equates to an average annual health care cost of approximately £200
per smoker, whilst in our study the cost amongst people with mental disorders was estimated around £320 per smoker. This suggests that the average direct medical costs were much higher in people with mental health disorders than in the general population.
Productivity lost due to smoking by people with mental health disorders imposes further economic costs in addition to direct health care expenditure. A number of studies have demonstrated that smokers have an increased level of absenteeism from work in the general population [27] . The most recent study has estimated the cost of productivity lost due to smoking related absence to be £2.5 billion in 2010 in the UK (Table 4) .
The estimated deaths, years of life lost and economic costs of smoking in this population are potentially almost entirely preventable through smoking cessation and harm reduction interventions. Smoking cessation is one of the most cost-effective public health interventions, and an estimated incremental cost per quality-adjusted life-year (QALY) of between £221 and £9,515, which is considerably lower than the informal NICE threshold for cost effective NHS treatments (£20,000 per QALY) [28] .
Data based on NHS Stop Smoking Services suggests that the cost per quitter was £220 in the UK in 2010/11 [29] , whereas the estimated average healthcare costs and productivity losses presented in this study was more than £650 per person annually due to smoking. However, the effectiveness of smoking cessation may differ in people with mental disorders compared to the general population due to heavy addiction to nicotine among people with mental disorders [6] . Further research is needed to explore the effectiveness and cost-effectiveness of smoking cessation in people with mental disorders.
In this study, the proportion of current and ex-smokers among people with SMD was obtained from a study conducted in 1996. Thus, we conducted a sensitivity analysis to £692 million for direct medical costs, £806 million for indirect morbidity costs and £779 million for indirect mortality costs.
The economic costs estimated above do not include the cost of accidental fires caused by discarded cigarettes, costs due to diseases caused by second-hand smoke exposure in mental health settings, or excess costs for psychotropic drug dose due to increased metabolism of some psychotropic medications in smokers. It is reported that the excess psychotropic medicine costs to the NHS due to smoking was £40 million [6] .
On the other hand, non-smokers live longer than smokers and impose a greater burden on health care resources especially in later ages. However, there is evidence that in general population smoking constitutes an economic burden to the society even when considering non-smokers longer life expectancy. [30] Further research is needed to examine more closely to the long-term cost of smoking and smoking cessation amongst people with mental disorders, incorporating the health benefits to the society as a whole.
It is clear that smoking in people with mental disorders in the UK imposes a significant economic burden and therefore that the development and implementation of smoking cessation interventions in this group should be a high priority. This economic case augments the ethical and clinical imperative of addressing smoking more systematically and effectively in this group and is over and above the health benefits in terms of quality and quantity of life which are enjoyed following smoking cessation.
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WHAT THIS PAPER ADDS
This study estimated the economic costs of the health effects of cigarette smoking amongst people with mental disorders in the UK based on the cost of illness approach.
The avoidable costs include direct healthcare costs, indirect morbidity costs and indirect mortality costs due to smoking-related diseases.
The result demonstrated that smoking in people with mental disorders in the UK imposes a significant economic burden and therefore that development and implementation of smoking cessation interventions in this group is a particularly high priority.
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